Does the media prefer NVAX or IPSC?

In the previous week, Novavax had 24 more articles in the media than Century Therapeutics. MarketBeat recorded 30 mentions for Novavax and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Novavax's score of 0.24 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IPSC or ALVO?

In the previous week, Alvotech had 6 more articles in the media than Century Therapeutics. MarketBeat recorded 12 mentions for Alvotech and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Alvotech's score of 0.69 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IPSC or AVBP more profitable?

Century Therapeutics' return on equity of -49.51% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% ArriVent BioPharma N/A -50.26% -46.66%

Does the media refer more to IPSC or AVBP?

In the previous week, ArriVent BioPharma had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for ArriVent BioPharma and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat ArriVent BioPharma's score of 1.29 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IPSC or REPL more profitable?

Century Therapeutics' return on equity of -49.51% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% Replimune Group N/A -159.32% -90.84%

Does the media favor IPSC or REPL?

In the previous week, Replimune Group had 19 more articles in the media than Century Therapeutics. MarketBeat recorded 25 mentions for Replimune Group and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Replimune Group's score of 0.47 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 5 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGEM or IPSC more profitable?

Century Therapeutics' return on equity of -49.51% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Century Therapeutics N/A -49.51% -38.09%

Does the media prefer CGEM or IPSC?

In the previous week, Cullinan Therapeutics had 7 more articles in the media than Century Therapeutics. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Cullinan Therapeutics' score of 1.23 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Century Therapeutics (IPSC) Competitors

$2.03 -0.20 (-8.97%)

As of 08/28/2026 04:00 PM Eastern

Compare

IPSC vs. NVAX, ALVO, AVBP, REPL, and CGEM

Should you buy Century Therapeutics stock or one of its competitors? Century Therapeutics's main competitors and comparable companies include Novavax (NVAX), Alvotech (ALVO), ArriVent BioPharma (AVBP), Replimune Group (REPL), and Cullinan Therapeutics (CGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Century Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Novavax has higher revenue and earnings than Century Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.36	$440.30M	-$1.52	N/A
Century Therapeutics	$109.16M	3.37	-$9.58M	-$0.93	N/A

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 51.19%. Century Therapeutics has a consensus price target of $4.75, indicating a potential upside of 133.99%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Century Therapeutics	N/A	-49.51%	-38.09%

Novavax has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Novavax had 24 more articles in the media than Century Therapeutics. MarketBeat recorded 30 mentions for Novavax and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Novavax's score of 0.24 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novavax and Century Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Alvotech?

Century Therapeutics (NASDAQ:IPSC) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Alvotech had 6 more articles in the media than Century Therapeutics. MarketBeat recorded 12 mentions for Alvotech and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Alvotech's score of 0.69 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Alvotech	-36.31%	-11.92%	-11.73%

Century Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Century Therapeutics currently has a consensus target price of $4.75, indicating a potential upside of 133.99%. Alvotech has a consensus target price of $7.50, indicating a potential upside of 51.52%. Given Century Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Century Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25

50.2% of Century Therapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alvotech has higher revenue and earnings than Century Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.37	-$9.58M	-$0.93	N/A
Alvotech	$588.90M	2.54	$27.92M	-$0.61	N/A

Summary

Century Therapeutics beats Alvotech on 9 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to ArriVent BioPharma?

Century Therapeutics (NASDAQ:IPSC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, ArriVent BioPharma had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for ArriVent BioPharma and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat ArriVent BioPharma's score of 1.29 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics' return on equity of -49.51% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Century Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Century Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 133.99%. ArriVent BioPharma has a consensus target price of $44.86, suggesting a potential upside of 48.68%. Given Century Therapeutics' higher probable upside, equities research analysts clearly believe Century Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Century Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.37	-$9.58M	-$0.93	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

Summary

Century Therapeutics beats ArriVent BioPharma on 10 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to Replimune Group?

Century Therapeutics (NASDAQ:IPSC) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Comparatively, 5.4% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Century Therapeutics' return on equity of -49.51% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Replimune Group	N/A	-159.32%	-90.84%

Century Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.37	-$9.58M	-$0.93	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Century Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Century Therapeutics currently has a consensus target price of $4.75, indicating a potential upside of 133.99%. Replimune Group has a consensus target price of $12.00, indicating a potential downside of 22.58%. Given Century Therapeutics' higher probable upside, equities research analysts plainly believe Century Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Replimune Group had 19 more articles in the media than Century Therapeutics. MarketBeat recorded 25 mentions for Replimune Group and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Replimune Group's score of 0.47 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	5 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Century Therapeutics beats Replimune Group on 9 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Century Therapeutics' return on equity of -49.51% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Century Therapeutics	N/A	-49.51%	-38.09%

Cullinan Therapeutics presently has a consensus target price of $32.86, indicating a potential upside of 51.42%. Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 133.99%. Given Century Therapeutics' higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Century Therapeutics	$109.16M	3.37	-$9.58M	-$0.93	N/A

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cullinan Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

In the previous week, Cullinan Therapeutics had 7 more articles in the media than Century Therapeutics. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 6 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.35 beat Cullinan Therapeutics' score of 1.23 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Century Therapeutics beats Cullinan Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$366.68M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.18	11.62	273.16	25.45
Price / Sales	3.37	1,295.87	605.06	76.64
Price / Cash	152.26	106.39	76.74	53.00
Price / Book	1.59	16.53	12.98	6.14
Net Income	-$9.58M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-1.93%	-0.31%	0.13%	-0.80%
1 Month Performance	-7.31%	9.80%	7.08%	4.13%
1 Year Performance	314.29%	55.66%	24.67%	15.17%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	2.2846 of 5 stars	$2.03 -9.0%	$4.75 +134.0%	+314.3%	$366.68M	$109.16M	N/A	170	News Coverage Positive News
NVAX Novavax	1.9447 of 5 stars	$9.44 +6.5%	$14.00 +48.4%	+24.0%	$1.56B	$413.80M	N/A	1,990	Trending News Options Volume Analyst Revision
ALVO Alvotech	3.0472 of 5 stars	$5.06 -3.6%	$7.50 +48.2%	-38.7%	$1.52B	$491.95M	N/A	1,460	High Trading Volume
AVBP ArriVent BioPharma	2.4755 of 5 stars	$30.87 +9.2%	$44.86 +45.3%	+57.8%	$1.52B	N/A	N/A	40	News Coverage
REPL Replimune Group	2.2665 of 5 stars	$15.69 +6.6%	$11.86 -24.4%	+187.0%	$1.47B	N/A	N/A	210	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. NVAX, ALVO, AVBP, REPL, and CGEM

How does Century Therapeutics compare to Novavax?

Summary

How does Century Therapeutics compare to Alvotech?

Summary

How does Century Therapeutics compare to ArriVent BioPharma?

Summary

How does Century Therapeutics compare to Replimune Group?

Summary

How does Century Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. NVAX, ALVO, AVBP, REPL, and CGEM

How does Century Therapeutics compare to Novavax?

Which has stronger earnings and valuation, NVAX or IPSC?

Do analysts recommend NVAX or IPSC?

Is NVAX or IPSC more profitable?

Which has more risk & volatility, NVAX or IPSC?

Do institutionals & insiders believe in NVAX or IPSC?

Does the media prefer NVAX or IPSC?

Summary

How does Century Therapeutics compare to Alvotech?

Does the media refer more to IPSC or ALVO?

Is IPSC or ALVO more profitable?

Which has more volatility & risk, IPSC or ALVO?

Do analysts recommend IPSC or ALVO?

Do institutionals and insiders believe in IPSC or ALVO?

Which has higher earnings & valuation, IPSC or ALVO?

Summary

How does Century Therapeutics compare to ArriVent BioPharma?

Does the media refer more to IPSC or AVBP?

Is IPSC or AVBP more profitable?

Which has more volatility & risk, IPSC or AVBP?

Do analysts recommend IPSC or AVBP?

Do institutionals and insiders hold more shares of IPSC or AVBP?

Which has preferable valuation and earnings, IPSC or AVBP?

Summary

How does Century Therapeutics compare to Replimune Group?

Do insiders & institutionals believe in IPSC or REPL?

Is IPSC or REPL more profitable?

Which has stronger earnings & valuation, IPSC or REPL?

Which has more risk and volatility, IPSC or REPL?

Do analysts rate IPSC or REPL?

Does the media favor IPSC or REPL?

Summary

How does Century Therapeutics compare to Cullinan Therapeutics?

Is CGEM or IPSC more profitable?

Do analysts rate CGEM or IPSC?

Which has higher valuation and earnings, CGEM or IPSC?

Do insiders & institutionals hold more shares of CGEM or IPSC?

Which has more risk and volatility, CGEM or IPSC?

Does the media prefer CGEM or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools